Amylyx Pharmaceuticals, Inc. AMLX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s accrued expenses?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported accrued expenses of $11.28M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s accrued expenses decreased by 6.5% year-over-year, from $12.07M to $11.28M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s accrued expenses?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s accrued expenses has grown at a 8.3% compound annual growth rate (CAGR), from $13.02M to $17.91M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.